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Abstract 
Introduction: In this study we estimated the rate and the trajectory of cognitive 
impairment in a naturalistic sample of outpatients with major depressive disorder 
(MDD) and bipolar disorder (BD) and its correlation with different variables.  
Materials and methods: An overall sample of 109 outpatients with MDD or BD was 
assessed for multiple clinical variables, including duration of untreated illness (DUI), 
and tested using the Montreal Cognitive Assessment (MoCA) during Major Depressive 
Episodes (MDE) and after remission. Correlations between MoCA scores and the 
clinical variables were then computed.  
Results: About 50% of patients with MDD and BD showed mild cognitive impairment 
during MDE. Improvement of cognitive function between depression and remission was 
significant, even though residual symptoms were observed especially in the most 
impaired patients. Of note, cognitive performance during depression was negatively 
associated with depression severity and DUI.  
Discussion: Present findings confirm available evidence about patterns of cognitive 
impairment in mood disorders, in terms of prevalence and persistence beyond remission 
in most severe cases. Moreover, a longer DUI was associated with worse cognitive 
performance during depression, and consequently with poorer outcome, underlining the 
importance of prompt treatment of these disorders also in light of a cognitive 
perspective. 
 
Keywords: bipolar disorder, cognitive dysfunction, duration of untreated illness, major 
depressive disorder, Montreal cognitive assessment 
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Introduction 
Over the last decades, the number of scientific publications addressing neurocognitive 
impairment in mood disorders has been constantly growing(Russo, Mahon, & Burdick, 
2015). It is now well established that cognitive impairment is one of the core features of 
mood disorders, emerging during depressive episodes in major depressive disorder 
(MDD) and during depressive and manic phases in bipolar disorder (BD). Moreover, 
there is evidence for the persistence of cognitive impairment beyond mood episodes 
during euthymia(Dell’Osso et al., 2015). A number of clinical characteristics has been 
associated with cognitive impairment in mood disorders and the severity of the 
impairment has been related to several clinical factors(McIntyre et al., 2013). First of 
all, age is an important moderator of cognitive performance with an inversely 
proportional relationship between age and cognitive performance(Lee, Hermens, Porter, 
& Redoblado-Hodge, 2012). Moreover, cognition of depressed patients is thought to be 
influenced by childhood traumatic events(Lemos-Miller & Kearney, 2006; Riso, 
Miyatake, & Thase, 2002), education level(Gildengers et al., 2012), age at 
onset(Herrmann, Le Masurier, & Ebmeier, 2008), duration of illness(Herrera-Guzman 
et al., 2010), frequency of depressive episodes(Gorwood, Corruble, Falissard, & 
Goodwin, 2008) and by psychiatric(Liu, Chiu, & Yang, 2010) and medical 
comorbidities(McIntyre et al., 2007)20,2. Another significant factor is the effect of 
psychotropic drugs(McIntyre et al., 2013): for instance, antidepressants have been 
associated with memory and verbal learning deficits, but with better cognitive 
flexibility(Lee et al., 2012). Indeed, evidence on the real effect of antidepressants on 
cognition is still inconclusive. It is also known that antipsychotics have been correlated 
with deficits in working memory(Baune & Renger, 2014). Cognitive impairment 
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characterizes both MDD and BD: few studies, however, have directly compared the 
cognitive profile of patients with MDD and BD during depressive episodes. In addition, 
these studies included patients regardless of the disease phase and produced conflicting 
evidence, suggesting in some cases a different profile of dysfunctions in unipolar versus 
bipolar patients (in terms of expression and severity), as well as overlapping deficits in 
other reports(Xu et al., 2012). 
Evidence in this field has been summarized in a recent metanalysis of the comparative 
studies of cognitive functioning in BD and MDD, performed by Samamè and colleagues 
(Samamé, Szmulewicz, Valerio, Martino, & Strejilevich, 2017), revealing that there 
might be no distinctive feature between BD and MDD patients in terms of 
neuropsychological profile. In fact, Authors found similar neuropsychological outcomes 
in the two disorders across eleven cognitive domains during depression. However, a 
significant heterogeneity in effect sizes was observed and studies included in the 
analyses had very limited sample sizes. 
Studies published after the metanalysis by Samamè and co-authors have still produced 
conflicting evidence. Specifically, in a recent study comparing the cognitive function of 
patients with MDD, BD, relatives of BD and MDD patients and healthy controls, Bo 
and colleagues did not find specific differences between unipolar and bipolar patients, 
but only differences in the degree of dysfunction (Bo et al., 2018). In contrast with these 
results, Mak and co-authors (Mak et al., 2018) found evidence of greater cognitive 
impairment in unipolar compared to bipolar depression, with regard to executive 
functions and psychomotor speed in drug-naive patients.  
Follow-up studies of longitudinal course of cognitive impairment are essential but 
difficult to carry out. With regard to BD, tThe few existing ones suggest that executive 
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functions and processing speed are the two domains stably altered over time in bipolar 
patients, regardless of change in psychiatric symptom severitycognitive impairment is 
stable over time in BD(Balanza-Martinez et al., 2005; Depp et al., 2008; Mur, Portella, 
Martinez-Aran, Pifarre, & Vieta, 2008). With regard to MDD, most comprehensive data 
from a recent meta-analysis suggest that memory and attention deficits persist in 
remission from a major depressive episode (Semkovska et al., 2019): nonetheless, the 
analyses in this study were conducted on remitted patients instead of a longitudinal 
assessment of patients from depression to remission. 
In this scenery, literature is inconclusive and it is still debated whether cognitive 
impairment is associated with distinct clinical features in MDD and BD patients, and if 
the two subtypes of mood disorders are characterized by different rates of cognitive 
impairment in clinical settings. 
 In this study, we used data from routine psychopathological and cognitive screening in 
order to estimate the rate, the nature and the longitudinal course of cognitive impairment 
in a naturalistic cohort of outpatients suffering from unipolar and bipolar depression. 
Moreover, we assessed the correlation of cognitive impairment in depressed and 
remitted patient with a range of socio-demographic and clinical characteristics, 
particularly age, age at onset, severity of depression and anxiety symptomatology, 
duration of illness and duration of untreated illness (DUI). A specific hypothesis we 
wanted to test regarded the relationship between DUI and cognitive impairment, 
considering the significant role DUI has demonstrated on outcome in several psychiatric 
disorders(Altamura, Dell’Osso, Mundo, & Dell’Osso, 2007). To the best of our 
knowledge, to date evidence regarding a specific association between DUI and 
cognitive impairment in mood disorders is still lacking.  
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A secondary endpoint was to highlight differences between the cognitive profile of 
unipolar and bipolar during and after a MDE. 
 
Materials and methods 
Eligibility for the study  
The present prospective, observational and naturalistic study was conducted at the 
Centre for the Diagnosis and Treatment of Depressive Disorders (CTDD) of ASST 
Fatebenefratelli-Sacco in Milan: an outpatient, tertiary psychiatric service dedicated to 
the treatment of patients with mood and anxiety disorders. In the study, both outpatients 
and patients undergoing day-hospital care were enrolled. 
Although conceived before its publication, we underline the design of the study fits 
most of the methodological criteria defined by the International Society for Bipolar 
Disorders (ISBD) task force in the guidelines for the study of cognitive disorders in 
Bipolar Disorder (Miskowiak et al., 2017), as well as those previously proposed by 
Burdick and colleagues (2015)(Burdick, Ketter, Goldberg, & Calabrese, 2015). 
Subjects of male and female gender, above the age of 18, satisfying the diagnosis of 
MDE (single or recurrent) within MDD or BD-I or BD-II were considered eligible for 
the study. Diagnoses were formulated through a structured clinical interview complying 
with the criteria of the Diagnostic and Statistical Manual of Mental Disorders - Fifth 
Edition (DSM-5). Exclusion criteria are reported in Table 1. Bipolar patients during a 
Mixed Episode as well as bipolar patients with subthreshold manic symptoms were 
excluded from the analyses. 
Through a retrospective chart review, both in paper and computerized form or, when 
necessary, through a direct interview with the subject enrolled in the study, the main 
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socio-demographic and clinical characteristics of the patients were collected in an 
electronic database (see Table 2). In particular, data on DUI were collected: as in 
previuos studies by our research group(Altamura, Dell’osso, D’Urso, et al., 2008; 
Altamura, Dell’osso, Vismara, & Mundo, 2008; Dell’Osso et al., 2016; Galimberti et 
al., 2019), defining it as the time elapsed between the psychiatric onset and the first 
adequate treatment for MDD or BD, that is an antidepressant in the first case, mono-
therapy with mood stabilizers or SGAs (or the combination of antidepressants with 
mood stabilizers or FGA/SGAs) in the latter case (Fountoulakis et al., 2017; Yatham et 
al., 2018). DUI was assessed during clinical interviews and cross-checked with data 
derived from paper medical records and/or Institutional electronic databases. When data 
about DUI weren’t collectable as well as in case of  low reliability of data (by 
researchers’ judgement), patients were excluded from the analyses. 
All subjects enrolled in the study provided informed consent to the collection of 
personal and sensitive data, as well as the consent to undergo the psychometric 
evaluation and cognitive test described below. 
 
Psychopathological assessment 
The severity of depressive symptomatology was assessed by administering the 21 items-
Hamilton Depression Rating Scale (HDRS)(Hamilton, 1960) at the time of study entry 
(depressive phase) and subsequently, repeatedly, until clinical remission (remission) 
was achieved (according to literature, remission was defined as a HDRS total score of 
less than 8). At the time of study entry (depression) and at remission (remission), the 
severity of the anxious component was also assessed by administering the Hamilton 
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Anxiety Rating Scale (HARS)(Hamilton, 2018). Clinical remission was considered 
complete upon the achievement of a concomitant score of HDRS<8 and HARS<7. 
HDRS and HARS were considered for the analyses of our study, but they were part of a 
more comprehensive psychopathological assessment including the Young Mania Rating 
Scale (YMRS)(Young, Biggs, Ziegler, & Meyer, 1978) we use to exclude bipolar 
patients with concomitant manic symptoms. 
 
Cognitive screening: the Montreal Cognitive Assessment (MoCA) 
In this study, cognitive performance was assessed through the Montreal Cognitive 
Assessment (MoCA), administered during the depressive episode and after clinical 
remission. 
The MoCA is a short screening test developed by Nasreddine and colleagues (2005) for 
the identification of mild cognitive impairment (or MCI)(Nasreddine et al., 2005). The 
MoCA examines six different cognitive domains, such as: executive functions, 
visuospatial abilities, attention, verbal fluency, memory and spatio-temporal orientation. 
The total score of the MoCA ranges from a minimum of 0 to a maximum of 30, 
providing a global assessment of the cognitive performance of the subject. In relation to 
the years of education, a score equal to or above 26 is considered normal(Nasreddine et 
al., 2005), and a supplementary point is added if years of education are less than 12. The 
average time to administer the test is usually around 10-15 minutes. 
The MoCA has good internal consistency with a Cronbach's alpha value of 
0.83(Nasreddine et al., 2005). Furthermore, the sensitivity and the specificity of the 
MoCA in identifying MCI were 90% and 87%, respectively. Finally, the positive (VPP) 
and negative (VPN) predictive value of the MoCA were 89% and 91% for MCI. 
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Among cognitive screening tests, the Mini Mental State Examination (MMSE)(Folstein, 
Folstein, & McHugh, 1975) is the most commonly used for the detection of cognitive 
impairment. However, the MMSE is considered less sensitive in detecting deficits in 
executive functions, attention and visuospatial domains(Mitchell, 2009; Nasreddine et 
al., 2005). Compared to the MMSE, the MoCA includes several tasks based on 
visuospatial material and procedures specifically aimed at evaluating executive 
functions and attention(Smith, Gildeh, & Holmes, 2007), as well as memory. 
The MoCA has proven to be a sensitive tool for screening patients with other forms of 
dementia, such as vascular dementia(Freitas, Simoes, Alves, Vicente, & Santana, 2012), 
dementia associated with Parkinson's disease(Hoops et al., 2009) and Frontotemporal 
Dementia(Freitas, Simoes, Alves, Duro, & Santana, 2012). In psychiatric practice, the 
MoCA has been used successfully to evaluate cognitive impairment in patients with 
depression, BD and schizophrenia(Musso, Cohen, Auster, & McGovern, 2014; Yang et 
al., 2018) as well as depressed patients undergoing electroconvulsive therapy 
(ECT)(Moirand et al., 2018). For these reasons, the MoCA was implemented in our 
daily clinical practice as a systematic cognitive screening tool. 
 
Statistical analysis 
The Kolmogorov-Smirnov and Shapiro-Wilk tests were performed to test the 
assumption of normal distribution of clinical and socio-demographic variables, as well 
as that of HDRS, HARS and MoCA scores. 
Socio-demographic and clinical characteristics were compared between MDD and BD 
patients the two groups using Mann-Whitney U non-parametric test for continuous 
variables and Chi-square test (χ2) for dichotomous variables. 
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Then, Mann-Whitney U test was used to analyse the differences between the scores of 
the single cognitive domains of the MoCA between the two groups and between the 
total scores of the scales for depression and anxiety. These analyses were conducted for 
both the depressive and remission-related scores 
The mentioned analyses were conducted separately for data collected at each time-point 
(during depression and after clinical remission).  
Furthermore, the statistical significance of the change of the MoCA total scores and of 
the individual cognitive domains from depressive phase to clinical remission was 
calculated using the Wilcoxon test. 
The same analyses were also performed comparing two groups of patients defined by 
the presence of a MoCA score in the depressive phase below 26/30: "bipolar patients 
with cognitive dysfunction" and "unipolar patients with cognitive dysfunction". 
In addition, the associations between MoCA score during depression and a series of 
socio-demographic and clinical variables were investigated, both for the group of 
patients with MDD and for the group with BD. Given the non-normal distribution of the 
values of the main variables, the strength of the association was calculated by means of 
the Spearman’s rho (ρ) correlation coefficients.  
For all analyses, the threshold for statistical significance was set at p<0.05.All statistical 
analyses were performed using IBM Statistical Package for Social Sciences version 
22.0. 
 
Results 
Sample characteristics 
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In total, 109 outpatients with MDE were eligible for the study, including 72 patients 
(66.1%) diagnosed with MDD and 37 patients (33.9%) with BD. The two groups of 
patients with MDD and BD were homogeneous with regard to most of the main socio-
demographic and clinical variables (see tables 2 and 3).  
A statistically significant difference emerged in terms of previous hospitalizations 
(χ2=14.924, p<0.001) and previous suicide attempts (χ2=4.688, p=0.030), which were 
higher in the group of BD patients, who also had more mood episodes compared to 
patients with MDD (U=566.0, Z =-4.028, p<0.001). 
Finally, in terms of medication status, patients with BD were more frequently treated 
with antipsychotics (χ2=5.541, p=0.019) and mood stabilizers (χ2=23.096, p<0.001), but 
less frequently with antidepressants (χ2=8.224, p=0.004) compared to patients with 
MDD. However, there was no difference in treatment with benzodiazepines (χ2=1.097, 
p=0.295). In our opinion, these differences reflect the naturalistic context in which the 
study was conducted. In fact, in clinical practice, MDD and BD are distinct by a 
different course of illness and by treatment strategies. We took into consideration these 
differences by conducting some analyses to weight their impact on the variables 
examined in the present study. 
During depression, mean HDRS score and mean HARS were respectively 27.35±6.05 
and 21.61±9.062 for MDD, and 26.62±6.45 and 18.68±7.32 for BD patients. Therefore, 
the study sample showed moderate to severe depressive symptomatology and mild to 
moderate anxious symptomatology, reflecting recruitment in a day-hospital service that 
is specifically dedicated to the treatment of severe forms of depression. No statistically 
significant differences emerged between the two groups with respect to depressive 
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(U=1265.5, Z=-0.311, p=0.756) nor to anxious symptomatology (U=1054.5, Z=-1.557, 
p=0.115).  
Mean duration of current MDE (or time to remission) was 79.77 days in the total 
sample, with no statistical significant difference between MDD and BD (MDD: 
77.43±34.85 vs BD: 84.32±37.84; U=1195.5, Z=-.875, p=.382). 
 
Effect of pharmacological treatments on cognitive performance 
With regard to medication status, our data show that patients with BD were more 
frequently treated with antipsychotics (χ2=5.541, p=0.019) and mood stabilizers 
(χ2=23.096, p<0.001), but less frequently with antidepressants (χ2=8.224, p=0.004) 
compared to patients with MDD. However, there was no difference in treatment with 
benzodiazepines (χ2=1.097, p=0.295). In our opinion, these differences reflect the 
naturalistic context in which the study was conducted. In fact, in clinical practice, MDD 
and BD are distinct by a different course of illness and by treatment strategies. We took 
into consideration these differences by conducting some analyses to weight their impact 
on the variables examined in the present study. 
As described, the present study was conducted in a naturalistic context: coherently, the 
two groups of patients with MDD and with BD showed statistically significant 
differences in terms of pharmacological treatment. In fact, according to international 
guidelines, treatment of bipolar depression differs from that of unipolar depression. In 
particular, use of antidepressants in bipolar depression is controversial and should be 
considered second choice or, at least, it should be administered in association with a 
mood-stabilizer(Pacchiarotti et al., 2013). For this reason, depressed patients were more 
frequently on antidepressants in our sample, whereas bipolar patients were more often 
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on antipsychotic and mood stabilizing treatment. More detailed analyses were therefore 
conducted to investigate the effect of these different treatment patterns on the cognitive 
performance in our sample. To do so, we divided the total sample by comparing MoCA 
scores between patients according to their medication status. No statistically significant 
differences emerged between the MoCA total scores of subjects treated with versus 
without antidepressants (U=489.5, Z=-0.343, p=0.731). There were no differences even 
for antipsychotics (U=1230, Z=-1.135, p=0.257), mood stabilizers (U=748.5, Z=-0.509, 
p=0.611) and benzodiazepines (U=1212.5, Z=-0.571, p=0.568). Moreover, patients with 
different types of treatment were homogeneous even when considering the single 
domains of the MoCA and even after the analysis was conducted considering MDD and 
BD separately. 
 
Cognitive performance during depression 
The mean MoCA total score (adjusted for education level) in the entire sample of 
depressed patients enrolled in the study was 24.04± 3.94, lower than the normality cut-
off of 26, as defined by the normative studies of the test. Globally, 50.5% of the 
subjects enrolled for the study had mild cognitive impairment, defined as a MoCA score 
of less than 26. In the two groups, 54.2% of patients with MDD and 59.4% of patients 
with BD had cognitive impairment, with a mean MoCA score of 24.11±4.04 and 
23.89±3.78 respectively, and no statistically significant difference (U=1274.0, Z=-
0.373, p=0.709). 
In literature, there are no defined cut-offs for each single domain of the MoCA, 
however, it was possible to consider scores based on their maximum value. The 
Memory domain score varies from 0 to 5; the domains of Visuospatial Skills and of the 
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Executive Functions from 0 to 4; the domains of Attention, Language and Orientation 
score from 0 to 6. All MoCA single domains scores are reported in Table 4. 
As mentioned, 54.2% of patients with MDD and 59.5% of patients with BD presented a 
picture of cognitive dysfunction during depression. Taking into consideration only these 
patients (with a MoCA total score below 26), the mean MoCA score was 21.18±3.16 for 
“MDD with cognitive dysfunction” and 21.59±3.11 for “BD with cognitive 
dysfunction”, with no statistically significant differences (U=379.5, Z=-0.751, 
p=0.453). Moreover, the two groups were homogeneous in terms of severity of 
depressive and anxious symptomatology, with a mean HDRS score of 24.79±6.42 and  
26.68±4.89, respectively in patients with MDD and with BD (U=341.5, Z=-1.317, 
p=0.188), and a HARS score of 20.42±8.92 and 18.73±7.56, respectively (U=373.0, Z=-
0.691, p=0.489). 
After analysing the six domains of the MoCA in the two subgroups, no statistically 
significant differences between MDD and BD were observed. 
Patients with “MDD with cognitive dysfunction” were on average older than patients 
with “MDD without cognitive dysfunction” (61.59 vs. 49.91, p=0.001), had higher age 
of onset (38.64 vs. 28.55, p=0.004) and longer duration of untreated illness 
(62.41±65.83 months vs. 56.73±105.0 months; U=434.5, Z=-2.393, p=0.017). On the 
other hand, no statistically significant difference emerged in terms of number of mood 
episodes (p=0.489) and severity of depressive symptoms (p=0.484) and anxiety 
(p=0.188). 
 Conversely, for BD, there were no statistically significant differences between “BD 
with cognitive dysfunction” and “BD without cognitive dysfunction” with regard to any 
of the socio-demographic variables taken into account. 
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Cognitive performance after clinical remission 
At time of clinical remission, the mean MoCA total score in the sample was 25.94±2.60. 
In patients diagnosed with MDD the mean score was 25.81±2.65 while it was 
26.22±2.50 in patients with BD. Therefore, patients with MDD were on average below 
MoCA threshold of normality, whereas patients with BD showed normal levels. 
However, this difference was not statistically significant (U=1188.0, Z=-0.930, 
p=0.353) nor clinically relevant, in our opinion. 
 Scores for the single cognitive domains of the MoCA at remission and comparison 
between MDD and BD are reported in Table 4. 
 
Change in cognitive performance from depression to remission 
All subjects enrolled in the study showed some improvement in the overall cognitive 
performance between depression and remission. There was indeed a statistically 
significant change in MoCA score both in the group of patients with MDD (Z=-7.326, 
p<0.001) and in the group with BD (Z=3.773, p<0.001). 
Taking into consideration the single MoCA domains separately, in MDD patients there 
was a statistically significant improvement in the domains of Memory (Z=-4.273, 
p<0.001), Executive Functions (Z=-3.431, p=0.001) and Attention (Z=-2.389, p=0.017), 
while there was no statistically significant variation in the domains of Visuospatial 
Abilities (Z = -0.576, p = 0.564), Verbal Fluency (Z=-1.531, p=0.126) and Orientation 
(Z=-0.401, p=0.688). 
Likewise, in BD patients, there was a statistical significant variation in Memory (Z=-
3.559, p<0.001), Executive Functions (Z=-3.431, p=0.001) and Attention (Z=-2.234, 
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p=0.020), while no significant changes were found in any other domain: Visuospatial 
Abilities (Z=-0.530, p=0.596), Verbal Fluency (Z=-1.554, p=0.120) and Orientation 
(Z=-1.734, p=0.083). 
Considering only patients with initial cognitive dysfunction (MoCA <26 in depressive 
phase), a statistically significant improvement of MoCA score was observed both in 
MDD (Z=-5.113, p<0.001) and in BD subjects (Z=-3.730, p<0.001). However, the 
mean value at the time of clinical remission was lower than the normal cut-off of the 
MoCA both in MDD and BD (24.54±2.53 and 25.36±2.75, respectively), suggesting a 
residual cognitive dysfunction in subjects with initial impairment. 
 
Correlations between cognitive performance and clinical-demographic variables 
One objective of our study was to search for correlations between cognitive 
performance and demographic and clinical variables, in a naturalistic sample 
representative of patients accessing specialized care for mood disorders. 
During depression, the MoCA score in the total sample was negatively correlated with 
HDRS (ρ=-0.474, p<0.001), but not with HARS score (ρ=0.064, p=0.708). 
Furthermore, the MoCA score was negatively correlated with DUI (ρ=-0.240, p=0.012). 
No other significant correlations emerged with the main demographic and clinical 
variables: age (ρ=-0.197, p=0.243), age of onset (ρ=-0.145, p=0.392), duration of illness 
(ρ=-0.007, p=0.966) and number of episodes of illness (ρ=-0.006, p=0.971). 
At remission, MoCA score was negatively correlated to three clinical variables: age 
(ρ=-0.313, p=0.001), HDRS score during depression (ρ=-0.365 p<0.001) and DUI (ρ=-
0.266, p=0.005). 
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During depression, MoCA score correlated with HDRS score both in patients with 
MDD (ρ=-0.382, p=0.001) and BD (ρ=-0.657, p<0.001), with no statistically significant 
differences between two groups (z=1.33, p=0.18). The MoCA score was also correlated 
with DUI (DDM: ρ=-0.237, p=0.045; DB: ρ=-0.462, p=0.004) without significant 
differences between the two groups (z=1.09, p=0.28). Furthermore, no other significant 
correlations emerged between global cognitive performance and specific demographic 
and clinical variables in the two separate groups. 
The DUI was not significantly correlated with any of the six cognitive domains, except 
with orientation in bipolar patients (ρ=-0.473, p=0.003). 
Finally, even performing the same analyses separately for patients with (MoCA <26 
during depression) versus without cognitive impairment, no statistically significant 
correlations emerged between DUI and single domains of the MoCA in unipolar nor in 
bipolar depression. 
 
Discussion 
Consistently with literature, the results of our study confirmed that patients suffering 
from depression, regardless of longitudinal diagnosis, are characterised by concomitant 
mild cognitive impairment. In our sample, more than 1 out of 2 depressed patients 
scored lower than normal on the MoCA screening, indicating the presence of a mild 
cognitive impairment. This result is in line with previous studies that have shown a 
prevalence of cognitive impairment around 25-50% of MDD cases(Gualtieri & Morgan, 
2008), even though the real prevalence of cognitive symptoms in depression is not fully 
clarified yet(Douglas et al., 2018; Trivedi & Greer, 2014). In a recent publication, 
during depressive episodes, Douglas and colleagues found prevalence rates of 14.7-
19 
 
52.9% and 32.2-64.4% in outpatients with MDD and BD respectively, depending on the 
definition of cognitive impairment considered(Douglas et al., 2018) and, therefore, 
substantially in line with our results. 
In this study, we also sought to investigate the clinical features associated with 
cognitive impairment in MDD and BD in a naturalistic context. Our study confirmed 
that a greater severity of depressive symptomatology is associated with a worse 
cognitive performance. This association is well established and was reported by 
McDermott and colleagues in a meta-analysis indicating a specific correlation between 
depression severity and episodic memory, executive functions and information 
processing speed(McDermott & Ebmeier, 2009) and, more recently, in a study 
comparing the cognitive function of MDD and BD patients(Bo et al., 2018). In our 
study, however, the severity of depressive symptomatology was not associated with any 
specific domain, either in MDD or in BD. This difference could be due to the lack of 
sensitivity of the MoCA in highlighting alterations of single domains, compared to its 
good sensitivity in relation to the overall performance. 
If the presence of a relationship between severity of depression and cognitive 
impairment has been already reported, the relationship between DUI and cognitive 
impairment during depression represents a novel finding emerging from our study. DUI 
is a clinical variable of great interest in clinical practice because, unlike many other 
factors, it is modifiable by providing early diagnosis and treatment to the patient. It is 
well established that a prolonged DUI is associated with a poorer outcome not only in 
schizophrenia(Buoli et al., 2013), but also in mood disorders(Altamura et al., 2007), 
anxiety disorders(Altamura, Dell’osso, D’Urso, et al., 2008; Dell’Osso, Camuri, 
Benatti, Buoli, & Altamura, 2013) and obsessive-compulsive disorder(Dell’Osso, Buoli, 
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Hollander, & Altamura, 2010). In our study, the average DUI was lower than that 
reported by most studies in the field, but consistent with the constant reduction of DUI 
over epochs of time observed in recent reports(Dell’Osso et al., 2016)(Dell’Osso et al., 
2017, 2016). Of note, present findings indicate that a prolonged DUI is also associated 
with a worse cognitive performance during depression. Hypothetically, this may 
represent one of the mechanisms through which depressed and bipolar patients, 
belatedly treated, experience a worse long-term outcome. Particularly in BD, this 
association is more consistent (the correlation value was greater in bipolar than in 
unipolar depression), probably since the onset of BD tends to occur in late childhood or 
early adulthood(Duffy, 2000) and more time can elapse before a correct diagnosis is 
formulated and an appropriate treatment prescribed(Goldberg & Ernst, 2002). 
In our study, not only during depression but even after remission, DUI was correlated 
with cognitive impairment: this result could reflect another detrimental effect through 
which DUI determines a poorer outcome in mood disorders. This might be summarized 
as follows: the longer the DUI, the higher the residuality of cognitive deficits after 
depression in mood disorders. 
One of the main objectives of our study was to highlight the distinctive features of 
unipolar and bipolar depression from a cognitive perspective, as, to date, evidence in 
this field is still limited and inconclusive. Our results highlighted similar patterns of 
cognitive impairment in unipolar and bipolar depression, quantitatively in terms of 
severity and qualitatively in terms of profile of cognitive domains involved. This result 
is also consistent with available evidence. Bearden and co-workers, for instance, 
showed overlapping patterns of cognitive impairment in unipolar and bipolar patients, 
which did not appear secondary to clinical status but rather related to a common 
Codice campo modificato
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pathophysiological genesis, suggestive of temporal lobe dysfunction (Bearden et al., 
2006). Subsequently, Hermens and colleagues analysed the neurocognitive profiles of 
unipolar and bipolar patients in early age, demonstrating similar deficits primarily 
referred to verbal memory impairment(Hermens, Naismith, Redoblado Hodge, Scott, & 
Hickie, 2010). More recently, Daniel and co-authors (2013) showed that neurocognitive 
performance did not differentiate patients affected by MDD from those suffering from  
BD-I(Daniel et al., 2013). Similar neurocognitive alterations have also been reported by 
Xu and colleagues (Xu et al., 2012) and, previously, by Sweeney and co-workers 
(Sweeney, Kmiec, & Kupfer, 2000). Indeed, in our opinion, the present study has the 
merit of having enrolled unipolar and bipolar patients during acute depressive episodes, 
whereas the cited studies enrolled rather heterogeneous samples of bipolar patients, 
consisting of mixed depressed, manic and euthymic patients. Furthermore, the sample 
sizes of some of the abovementioned studies were smaller than our sample and, 
consequently, the results less generalizable. 
It is noteworthy to mention another significant difference of our study compared to 
those available in literature. To date, cross-sectional studies on cognition in unipolar 
and bipolar depression have been using extensive batteries of neuropsychological tests, 
while in our study we used a quick and easy cognitive screening test for daily clinical 
practice. Although the assessment through neuropsychological tests is preferable for a 
more exhaustive analysis of patients' cognitive impairment, we believe the results of the 
present study reiterate the usefulness of the MoCA as a screening tool in daily clinical 
practice, in order to estimate the degree of cognitive impairment associated with 
depression.  
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Our results should be interpreted in light of the following limitations. First of all, one 
possible limitation lies in the lack of a control group of healthy subjects to allow for 
comparison analyses with patients with MDD and BD. Moreover, the naturalistic 
context in which the study was conducted determined the enrollment of two groups of 
patients that, although homogeneous for most of the clinical-demographic variables, had 
some peculiarities due to the different course and to the different treatment patterns. To 
date, the effect of drug therapy on cognitive functions is still uncertain due to the 
limited number of studies on this topic (Senturk Cankorur, Demirel, & Atbasoglu, 
2017). Metanalytic evidence suggests that antidepressants have positive cognitive 
effects on psychomotor speed and on delayed recall (Rosenblat, Kakar, & McIntyre, 
2015). Conversely, antipsychotics have generally been imputed detrimental effects on 
cognition, although controversies between experts in this field still remain (Donaldson, 
Goldstein, Landau, Raymont, & Frangou, 2003; Frangou, Donaldson, Hadjulis, Landau, 
& Goldstein, 2005; Glahn et al., 2007; Martinez-Aran et al., 2008). 
Furthermore, the widespread use of poly-therapies in the BD (and in part in MDD) 
makes it difficult to estimate the impact of any single drug on cognition. In our study, 
however, we conducted some sub-analyses to overcome these biases, excluding between 
groups differences and within diagnostic medication-dependent cognitive variability. 
The correlational design of the study may also be considered as a limitation as well as 
the lack of .control for group differences in number of rates of hospitalizations and 
number of previous mood episodes. Finally, the sample size of our study was relatively 
small, which is why further clinical trials on larger samples are warranted to confirm the 
evidence that emerged from our study. 
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In conclusion, patients with MDD and BD had similar rates and patterns of cognitive 
impairment during depression, both in terms of severity and alterations of specific 
cognitive domains, that particularly affect executive functions and memory. The 
severity of cognitive deficits was related to the severity of depressive symptomatology 
and tended to improve with remission of depressive symptoms. Nonetheless, patients 
with greater cognitive impairment during depression had residual cognitive deficits after 
remission. 
DUI could represent a key factor in determining cognitive impairment during depressive 
episodes, as patients for whom appropriate treatment was delayed experienced greater 
cognitive impairment than those promptly treated. The relationship of cognitive 
impairment with the DUI seemed to be particularly (but not only) significant for BD. 
 
Keypoints 
 Although distinct entities, unipolar and bipolar depression determine similar 
patterns of cognitive impairment in terms of severity and types of altered 
domains. 
 Depression (but not anxiety) severity is associated with cognitive performance 
in depression. 
 Prolonged duration of untreated illness is associated with more severe cognitive 
impairment during depression, particularly but not specifically in bipolar 
disorder. 
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TABLES 
Table 1. List of inclusion and exclusion criteria 
Inclusion criteria 
Male or female gender 
Age>18 
Diagnosis of major depressive episode (MDE) 
Longitudinal diagnosis of major depressive disorder or bipolar disorder I or II according to DSM-5 
criteria 
Exclusion criteria 
Diagnosis of Mixed Episode and/or subthreshold manic symptoms 
Clinically relevant learning or reading disability, dyslexia, illiteracy  
Diagnosis of cognitive disorder 
History of moderate to severe head injury 
Uncontrolled thyroid dysfunction 
Recent alcohol or substance abuse 
Concomitant therapy with high dose anticholinergics  
Concomitant therapy with benzodiazepines at a dosage equal or higher than diazepam 7.5 mg/day 
Electroconvulsive therapy within 6 months 
 
 
 
Table 2. Socio-demographic characteristics of the sample divided in two diagnostic groups 
 MDD BD p 
Sample size 72 37  
Gender, f% 65.3% 70.3% .600 
Age, mean±SD 56.24±14.51 56.89±10.02 .602 
Marital status, % 
Unmarried 15.3% 27.0% .111 
Married 62.5% 59.5% 
Divorced 11.1% 7.3% 
Widow 11.1% 6.2% 
Education, % 
Primary school 9.7% 8.1% .904 
Secondary school 6.4% 21.6% 
High school 41.7% 48.6% 
University 22.2% 21.6% 
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Employment status, % 
Unemployed 20.8% 27.0% .744 
Employed 41.7% 32.4% 
Retired 37.5% 40.5% 
Nationality, italian % 93.1% 97.3% .358 
Abbreviations: MDD, Major Depressive Disorder; BD, Bipolar Disorder; SD: standard deviation. 
 
Table 3. Clinical characteristics of the sample divided in two diagnostic groups 
 MDD BD p 
Family history for psychiatric 
disorders, % positive 
63.9% 75.7% .212 
Age at onset, mean±SD 34.15±14.94 30.0±12.89 .224 
DUI) in months, mean±SD 59.81±84.43 63.51±73.33 .074 
Duration of illness in years, 
mean±SD 
22.22±13.59 26.89±12.10 .087 
Psychiatric comorbidities, % 27.6% 13.5% .091 
Comorbidity with personality disorders, % 
None 76.4% 73.0% .463 
Cluster A 1.4% 5.4% 
Cluster B 13.9% 10.8% 
Cluster C 5.6% 2.7% 
Not specified 2.8% 8.1% 
Medical comorbidities, % present 48.6% 40.5% .389 
History of psychosis, positive % 19.4% 27.0% .361 
History of alcohol abuse, positive % 5.6% 13.5% .153 
History of substance abuse, positive 
% 
11.1% 2.7% .131 
Number of episodes of illness, 
mean±SD 
3.38±1.84 5.57±3.33 .001 
Duration of current MDE, days 77.43±34.85 84.32±37.84 .382 
Previous hospitalizations, yes %  22.2% 59.5% <.001 
Previous suicide attempts, yes % 26.4% 45.9% .030 
Psychopharmacological treatment 
Antidepressants, % 93.1% 75.7% <.001 
Antipsychotics, % 34.7% 59.5% .019 
Mood stabilizers, % 4.2% 40.5% .004 
Benzodiazepines, % 66.7% 56.8% .295 
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Abbreviations: MDD, Major Depressive Disorder; BD, Bipolar Disorder; DUI, Duration of untreated illness; MDE: 
Major Depressive Episode; SD: standard deviation. 
 
Table 4. Mean scores of MoCA single domains during depression and remission. 
 DEPRESSION REMISSION 
 Maximum 
values 
MDD BD p MDD BD p 
Memory 5 2.35±1.71 2.32±1.58 .902 3.36±1.24 3.43±1.09 .837 
Visuospatial 
abilities 
4 2.81±1.15 2.89±1.27 .514 2.90±0.92 3.00±0.94 .543 
Executive 
functions 
4 2.85±1.08 2.70±1.31 .679 3.49±0.69 3.57±0.65 .541 
Attention 6 5.40±0.93 5.30±1.24 .823 5.69±0.62 5.70±0.66 .908 
Verbal 
fluency 
6 5.01±1.11 5.11±0.94 .862 5.21±1.03 5.38±0.83 .589 
Orientation 6 5.81±0.60 5.68±0.63 .126 5.75±0.73 5.89±0.32 .393 
MoCA total 
score 
30 24.11±4.04 23.89±3.78 .709 25.81±2.65 26.22±2.50 .353 
Abbreviations: MDD, Major Depressive Disorder; BD, Bipolar Disorder; MoCA, Montreal Cognitive Assessment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
